{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:37Z","timestamp":1793228257112,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Programmed cell death 1 ligand 1 (PD-L1) is a ligand of programmed cell death 1 (PD-1) that functions as an immune checkpoint by down-regulating immune responses. To determine whether PD-L1 is a therapy target in vitiligo treatment, Pmel-1 vitiligo mice were treated with a PD-L1 fusion protein. Treatment with this fusion protein significantly reversed\/suppressed depigmentation development in adult Pmel-1 mice. Mechanistically, enrichment of regulatory T cells (Treg) in the skin was detected after PD-L1 fusion protein treatment in Pmel-1 mice. Furthermore, Tregs abundance was also increased in both the spleen and circulation of Pmel-1 mice treated with PD-L1. These data indicate that PD-L1 protein therapy inhibits the immune response and reverses depigmentation development in Pmel-1 vitiligo mice.<\/jats:p>","DOI":"10.1038\/s41598-018-19407-w","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T08:15:35Z","timestamp":1516349735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-8329","authenticated-orcid":false,"given":"Xiao","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"19407_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1078\/0171-9335-00423","volume":"83","author":"J Steitz","year":"2004","unstructured":"Steitz, J., Wenzel, J., Gaffal, E. & Tuting, T. Initiation and regulation of CD8+ T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur. J. Cell Biol. 83, 797\u2013803 (2004).","journal-title":"Eur. J. Cell Biol."},{"key":"19407_CR2","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn, J. G. et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. 129, 2220\u20132232 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"19407_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/jid.2014.529","volume":"135","author":"P Agarwal","year":"2015","unstructured":"Agarwal, P. et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J. Invest. Dermatol. 135, 1080\u20131088 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"19407_CR4","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/jid.2015.26","volume":"135","author":"JM Eby","year":"2015","unstructured":"Eby, J. M. et al. CCL22 to activate treg migration and suppress depigmentation in vitiligo. J. Invest. Dermatol. 135, 1574\u20131580 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"19407_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677\u2013704 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"19407_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"19407_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261\u2013268 (2001).","journal-title":"Nat. Immunol."},{"key":"19407_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/intimm\/8.5.773","volume":"8","author":"H Nishimura","year":"1996","unstructured":"Nishimura, H. et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int. Immunol. 8, 773\u2013780 (1996).","journal-title":"Int. Immunol."},{"key":"19407_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765\u2013772 (1996).","journal-title":"Int. Immunol."},{"key":"19407_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.it.2013.07.003","volume":"34","author":"S Ceeraz","year":"2013","unstructured":"Ceeraz, S., Nowak, E. C. & Noelle, R. J. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 34, 556\u2013563 (2013).","journal-title":"Trends Immunol"},{"key":"19407_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.jaci.2015.11.021","volume":"137","author":"JH Kim","year":"2016","unstructured":"Kim, J. H. et al. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells. J. Allergy Clin. Immunol. 137, 1466\u20131476 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"19407_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4049\/jimmunol.1500448","volume":"195","author":"Y Imai","year":"2015","unstructured":"Imai, Y. et al. Cutting edge: PD-1 regulates imiquimod-induced psoriasiform dermatitis through inhibition of IL-17A expression by innate gammadelta-low T cells. J. Immunol. 195, 421\u2013425 (2015).","journal-title":"J. Immunol."},{"key":"19407_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1600-065X.2008.00637.x","volume":"223","author":"TM Brusko","year":"2008","unstructured":"Brusko, T. M., Putnam, A. L. & Bluestone, J. A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223, 371\u2013390 (2008).","journal-title":"Immunol. Rev."},{"key":"19407_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.0105-2896.2006.00417.x","volume":"212","author":"C Baecher-Allan","year":"2006","unstructured":"Baecher-Allan, C. & Hafler, D. A. Human regulatory T cells and their role in autoimmune disease. Immunol. Rev. 212, 203\u2013216 (2006).","journal-title":"Immunol. Rev."},{"key":"19407_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/jid.2013.540","volume":"134","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee, S. et al. A quantitative increase in regulatory T cells controls development of vitiligo. J. Invest. Dermatol. 134, 1285\u20131294 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"19407_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1087-0024.2004.00825.x","volume":"9","author":"IC Le Poole","year":"2004","unstructured":"Le Poole, I. C., Wankowicz-Kalinska, A., van den Wijngaard, R. M., Nickoloff, B. J. & Das, P. K. Autoimmune aspects of depigmentation in vitiligo. J. Investig. Dermatol. Symp. Proc. 9, 68\u201372 (2004).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"19407_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1034\/j.1600-0749.2003.00038.x","volume":"16","author":"A Wankowicz-Kalinska","year":"2003","unstructured":"Wankowicz-Kalinska, A., Le Poole, C., van den Wijngaard, R., Storkus, W. J. & Das, P. K. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res. 16, 254\u2013260 (2003).","journal-title":"Pigment Cell Res."},{"key":"19407_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","volume":"83","author":"A Wankowicz-Kalinska","year":"2003","unstructured":"Wankowicz-Kalinska, A. et al. Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest. 83, 683\u2013695 (2003).","journal-title":"Lab Invest."},{"key":"19407_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1172\/JCI5857","volume":"103","author":"JR Abrams","year":"1999","unstructured":"Abrams, J. R. et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103, 1243\u20131252 (1999).","journal-title":"J. Clin. Invest."},{"key":"19407_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1084\/jem.192.5.681","volume":"192","author":"JR Abrams","year":"2000","unstructured":"Abrams, J. R. et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192, 681\u2013694 (2000).","journal-title":"J. Exp. Med."},{"key":"19407_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","volume":"28","author":"V Sibaud","year":"2016","unstructured":"Sibaud, V. et al. Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr. Opin. Oncol. 28, 254\u2013263 (2016).","journal-title":"Curr. Opin. Oncol."},{"key":"19407_CR22","doi-asserted-by":"publisher","first-page":"e006450","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota, K. et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open 5, e006450, https:\/\/doi.org\/10.1136\/bmjopen-2014-006450 (2015).","journal-title":"BMJ Open"},{"key":"19407_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1084\/jem.20030590","volume":"198","author":"WW Overwijk","year":"2003","unstructured":"Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569\u2013580 (2003).","journal-title":"J. Exp. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19407-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19407-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19407-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T20:25:36Z","timestamp":1671567936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19407-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19407"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-19407-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]},"assertion":[{"value":"3 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1605"}}